This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Michael Roy - Innovator in Oncological Treatments
Introduction
Michael Roy is a notable inventor based in Southbank, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for oncological diseases.
Latest Patents
Michael Roy holds a patent for his invention titled "Proteolysis targeting chimera (PROTACS) as degraders of SMARCA2 and/or SMARCA4." This invention encompasses compounds of a specific formula, which are designed to act as degraders of SMARCA2 and/or SMARCA4. The patent details their use in pharmaceutical compositions and their application as medicaments, especially for the treatment and prevention of oncological diseases. He has 1 patent to his name.
Career Highlights
Michael Roy is currently employed at Boehringer Ingelheim International GmbH, where he continues to work on groundbreaking research in the pharmaceutical industry. His work focuses on developing innovative solutions that address critical health challenges.
Collaborations
Throughout his career, Michael has collaborated with esteemed colleagues, including Alessio Ciulli and Christian Dank. These partnerships have contributed to the advancement of his research and the successful development of his inventions.
Conclusion
Michael Roy is a prominent figure in the field of pharmaceutical innovation, with a focus on oncological treatments. His contributions through patents and collaborations highlight his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile